Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
Dazhi Liu,1 Michael Offin,2 Stephen Harnicar,1 Bob T Li,2 Alexander Drilon2 1Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell...
Enregistré dans:
Auteurs principaux: | , , , , |
---|---|
Format: | Livre |
Publié: |
Dove Medical Press,
2018-07-01T00:00:00Z.
|
Sujets: | |
Accès en ligne: | Connect to this object online. |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Internet
Connect to this object online.3rd Floor Main Library
Cote: |
A1234.567 |
---|---|
Exemplaire 1 | Disponible |